{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T15:17:12Z","timestamp":1748359032464},"reference-count":104,"publisher":"Harborside Press, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p>Although children, adolescents, and young adults with newly diagnosed B-cell non-Hodgkin\u2019s lymphoma enjoy excellent overall survival with current chemoimmunotherapy, those with relapsed and\/or refractory disease have a dismal prognosis. Although most clinicians would agree that hematopoietic progenitor cell transplantation after reinduction therapy is frontline therapy for these patients, there is no consensus as to what type of hematopoietic progenitor cell transplantation promises the best event-free and overall survival. This review outlines the disparate types of stem cell therapy that have been used in this difficult-to-treat population as well as the role of maintenance and CAR T-cell therapy in conjunction with stem cell therapy.<\/jats:p>","DOI":"10.6004\/jnccn.2020.7617","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T19:25:28Z","timestamp":1596655528000},"page":"1135-1142","source":"Crossref","is-referenced-by-count":1,"title":["Hematopoietic Progenitor Cell Transplantation in Children, Adolescents, and Young Adults With Relapsed Mature B-Cell NHL"],"prefix":"10.6004","volume":"18","author":[{"given":"Aliza","family":"Gardenswartz","sequence":"first","affiliation":[{"name":"Departments of aPediatrics,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell S.","family":"Cairo","sequence":"additional","affiliation":[{"name":"Departments of aPediatrics,"},{"name":"bPathology,"},{"name":"cMedicine,"},{"name":"dMicrobiology and Immunology, and"},{"name":"eCell Biology and Anatomy, Maria Fareri Children\u2019s Hospital at Westchester Medical Center, New York Medical College, Valhalla, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"ref521","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1182\/blood-2002-05-1483","article-title":"A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma","volume":"101","author":"Levine","year":"2003","journal-title":"Blood"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00277-016-2671-5","article-title":"Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma","volume":"95","author":"Hohloch","year":"2016","journal-title":"Ann Hematol"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.13040","article-title":"Rituximab with chemotherapy in children and adolescents with central nervous system and\/or bone marrow-positive Burkitt lymphoma\/leukaemia: a Children\u2019s Oncology Group Report","volume":"167","author":"Goldman","year":"2014","journal-title":"Br J Haematol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.bbmt.2010.11.017","article-title":"Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study","volume":"17","author":"Monjanel","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jamaoncol.2018.6278","article-title":"Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT","volume":"5","author":"Kanate","year":"2019","journal-title":"JAMA Oncol"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.2012.47.1862","article-title":"Rituximab purging and\/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation","volume":"31","author":"Pettengell","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref651","article-title":"Role of HSCT in children and adolescents with refractory or relapsed NHL [abstract]","volume":"182","author":"Burkhardt","year":"2018","journal-title":"Br J Haematol"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/sj.bmt.1705948","article-title":"Stem cell transplantation for pediatric lymphoma: past, present and future","volume":"41","author":"Bradley","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/bjh.15753","article-title":"Advances in cellular and humoral immunotherapy - implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma","volume":"185","author":"Chu","year":"2019","journal-title":"Br J Haematol"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3324\/haematol.2014.121434","article-title":"Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective \u201cLymphomes Malins B\u201d protocols. A Soci\u00e9t\u00e9 Fran\u00e7aise des Cancers de l\u2019Enfant study","volume":"100","author":"Jourdain","year":"2015","journal-title":"Haematologica"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-Cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bbmt.2010.07.002","article-title":"Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children\u2019s Oncology Group study A5962","volume":"17","author":"Harris","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood.V90.8.2921","article-title":"High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt\u2019s lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry","volume":"90","author":"Ladenstein","year":"1997","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbmt.2009.09.021","article-title":"Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents","volume":"16","author":"Gross","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/17474086.2019.1596793","article-title":"Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma","volume":"12","author":"Dahi","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.3324\/haematol.2015.129452","article-title":"Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients","volume":"100","author":"Crocchiolo","year":"2015","journal-title":"Haematologica"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"key":"ref901","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719841581","article-title":"CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products","volume":"10","author":"Chavez","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2006.06004.x","article-title":"Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents\u2014a Berlin-Frankfurt-M\u00fcnster group report","volume":"133","author":"Woessmann","year":"2006","journal-title":"Br J Haematol"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3324\/haematol.2014.121434","article-title":"Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective \u201cLymphomes Malins B\u201d protocols. A Soci\u00e9t\u00e9 Fran\u00e7aise des Cancers de l\u2019Enfant study","volume":"100","author":"Jourdain","year":"2015","journal-title":"Haematologica"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.3324\/haematol.2015.129452","article-title":"Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients","volume":"100","author":"Crocchiolo","year":"2015","journal-title":"Haematologica"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"e27962","DOI":"10.1002\/pbc.27962","article-title":"Brentuximab vedotin as consolidation after hematopoietic cell transplant for relapsed Hodgkin lymphoma in pediatric patients","volume":"66","author":"Flerlage","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1470-2045(19)30091-9","article-title":"Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study","volume":"20","author":"Tilly","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1200\/JCO.1988.6.7.1118","article-title":"High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin\u2019s lymphoma","volume":"6","author":"Philip","year":"1988","journal-title":"J Clin Oncol"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/bjh.15753","article-title":"Advances in cellular and humoral immunotherapy - implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma","volume":"185","author":"Chu","year":"2019","journal-title":"Br J Haematol"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"key":"ref1041","first-page":"353","article-title":"Bone marrow transplantation in 46 pediatric patients with non-Hodgkin\u2019s lymphoma","volume":"15","author":"Bureo","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.bbmt.2010.11.017","article-title":"Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study","volume":"17","author":"Monjanel","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbmt.2009.09.021","article-title":"Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents","volume":"16","author":"Gross","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/bloodadvances.2018026203","article-title":"Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients","volume":"3","author":"Naik","year":"2019","journal-title":"Blood Adv"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s11899-019-00544-6","article-title":"Driving the CAR to the bone marrow transplant program","volume":"14","author":"Dave","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.bbmt.2012.10.003","article-title":"Advances in hematopoietic stem cell transplantation in childhood and adolescent lymphomas","volume":"19","author":"Cairo","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00277-006-0169-2","article-title":"Autologous peripheral blood stem cell transplantation in children with non-Hodgkin\u2019s lymphoma: a report from the Korean society of pediatric hematology-oncology","volume":"85","author":"Won","year":"2006","journal-title":"Ann Hematol"},{"key":"ref981","article-title":"Early response data for pediatric patients with non-Hodgkin lymphoma treated with CD19 chimeric antigen receptor (CAR) T-cells [abstract]","volume":"182","author":"Rivers","year":"2018","journal-title":"Br J Haematol"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hon.2069","article-title":"XI. How to treat children and adolescents with relapsed non-Hodgkin lymphoma?","volume":"31","author":"Woessmann","year":"2013","journal-title":"Hematol Oncol"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00277-016-2671-5","article-title":"Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma","volume":"95","author":"Hohloch","year":"2016","journal-title":"Ann Hematol"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2000.18.23.3918","article-title":"Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma","volume":"18","author":"Carella","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/pbc.24722","article-title":"Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation","volume":"60","author":"Giulino-Roth","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-Cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bbmt.2010.07.002","article-title":"Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children\u2019s Oncology Group study A5962","volume":"17","author":"Harris","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1200\/JCO.1988.6.7.1118","article-title":"High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin\u2019s lymphoma","volume":"6","author":"Philip","year":"1988","journal-title":"J Clin Oncol"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-1-4939-3684-7_18","article-title":"Modification of expanded NK cells with chimeric antigen receptor mRNA for adoptive cellular therapy","volume":"1441","author":"Chu","year":"2016","journal-title":"Methods Mol Biol"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma","volume":"30","author":"Gisselbrecht","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref471","first-page":"465","article-title":"High-dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non-Hodgkin\u2019s lymphoma","volume":"8","author":"Loiseau","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/bjh.15491","article-title":"Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB\/LMB 96: a report from the FAB\/LMB 96 study group","volume":"182","author":"Cairo","year":"2018","journal-title":"Br J Haematol"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1200\/JCO.2007.15.5887","article-title":"Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse\/refractory Hodgkin\u2019s lymphoma: results of the prospective multicenter H96 trial by the GELA\/SFGM study group","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bbmt.2015.05.016","article-title":"Phase II trial of tandem high-dose chemotherapy with autologous stem cell transplantation followed by reduced-intensity allogeneic stem cell transplantation for patients with high-risk lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00277-011-1199-y","article-title":"Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue","volume":"90","author":"Hohloch","year":"2011","journal-title":"Ann Hematol"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/MPH.0000000000001479","article-title":"What is the role of hematopoietic cell transplantation (HCT) for pediatric acute lymphoblastic leukemia (ALL) in the age of chimeric antigen receptor T-cell (CART) therapy?","volume":"41","author":"Taraseviciute","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/bjh.15491","article-title":"Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB\/LMB 96: a report from the FAB\/LMB 96 study group","volume":"182","author":"Cairo","year":"2018","journal-title":"Br J Haematol"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrclinonc.2015.187","article-title":"Novel immunotherapies in lymphoid malignancies","volume":"13","author":"Batlevi","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"ref1031","first-page":"465","article-title":"High-dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non-Hodgkin\u2019s lymphoma","volume":"8","author":"Loiseau","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.bbmt.2017.12.798","article-title":"Tandem autologous hematopoietic cell transplantation for patients with primary progressive or recurrent Hodgkin lymphoma: a SWOG and Blood and Marrow Transplant Clinical Trials Network phase II trial (SWOG S0410\/BMT CTN 0703)","volume":"24","author":"Smith","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"key":"ref341","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719841581","article-title":"CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products","volume":"10","author":"Chavez","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrclinonc.2015.187","article-title":"Novel immunotherapies in lymphoid malignancies","volume":"13","author":"Batlevi","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.2012.47.1862","article-title":"Rituximab purging and\/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation","volume":"31","author":"Pettengell","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.bbmt.2012.10.003","article-title":"Advances in hematopoietic stem cell transplantation in childhood and adolescent lymphomas","volume":"19","author":"Cairo","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.bbmt.2017.12.798","article-title":"Tandem autologous hematopoietic cell transplantation for patients with primary progressive or recurrent Hodgkin lymphoma: a SWOG and Blood and Marrow Transplant Clinical Trials Network phase II trial (SWOG S0410\/BMT CTN 0703)","volume":"24","author":"Smith","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/bmt.2012.116","article-title":"Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin\u2019s lymphoma","volume":"48","author":"Crocchiolo","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-1-4939-3684-7_18","article-title":"Modification of expanded NK cells with chimeric antigen receptor mRNA for adoptive cellular therapy","volume":"1441","author":"Chu","year":"2016","journal-title":"Methods Mol Biol"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1182\/blood-2002-05-1483","article-title":"A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma","volume":"101","author":"Levine","year":"2003","journal-title":"Blood"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/17474086.2019.1596793","article-title":"Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma","volume":"12","author":"Dahi","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bbmt.2015.05.016","article-title":"Phase II trial of tandem high-dose chemotherapy with autologous stem cell transplantation followed by reduced-intensity allogeneic stem cell transplantation for patients with high-risk lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s11899-019-00544-6","article-title":"Driving the CAR to the bone marrow transplant program","volume":"14","author":"Dave","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma","volume":"30","author":"Gisselbrecht","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2000.18.23.3918","article-title":"Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma","volume":"18","author":"Carella","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/bmt.2012.116","article-title":"Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin\u2019s lymphoma","volume":"48","author":"Crocchiolo","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/bloodadvances.2018026203","article-title":"Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients","volume":"3","author":"Naik","year":"2019","journal-title":"Blood Adv"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2006.06004.x","article-title":"Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents\u2014a Berlin-Frankfurt-M\u00fcnster group report","volume":"133","author":"Woessmann","year":"2006","journal-title":"Br J Haematol"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","article-title":"Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents","volume":"109","author":"Cairo","year":"2007","journal-title":"Blood"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.13040","article-title":"Rituximab with chemotherapy in children and adolescents with central nervous system and\/or bone marrow-positive Burkitt lymphoma\/leukaemia: a Children\u2019s Oncology Group Report","volume":"167","author":"Goldman","year":"2014","journal-title":"Br J Haematol"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1200\/JCO.2007.15.5887","article-title":"Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse\/refractory Hodgkin\u2019s lymphoma: results of the prospective multicenter H96 trial by the GELA\/SFGM study group","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jamaoncol.2018.6278","article-title":"Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT","volume":"5","author":"Kanate","year":"2019","journal-title":"JAMA Oncol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hon.2069","article-title":"XI. How to treat children and adolescents with relapsed non-Hodgkin lymphoma?","volume":"31","author":"Woessmann","year":"2013","journal-title":"Hematol Oncol"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00277-006-0169-2","article-title":"Autologous peripheral blood stem cell transplantation in children with non-Hodgkin\u2019s lymphoma: a report from the Korean society of pediatric hematology-oncology","volume":"85","author":"Won","year":"2006","journal-title":"Ann Hematol"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/pbc.24722","article-title":"Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation","volume":"60","author":"Giulino-Roth","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bmt.1701596","article-title":"Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT)","volume":"23","author":"Fanin","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bmt.1701596","article-title":"Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT)","volume":"23","author":"Fanin","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"ref91","article-title":"Role of HSCT in children and adolescents with refractory or relapsed NHL [abstract]","volume":"182","author":"Burkhardt","year":"2018","journal-title":"Br J Haematol"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00277-011-1199-y","article-title":"Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue","volume":"90","author":"Hohloch","year":"2011","journal-title":"Ann Hematol"},{"key":"ref421","article-title":"Early response data for pediatric patients with non-Hodgkin lymphoma treated with CD19 chimeric antigen receptor (CAR) T-cells [abstract]","volume":"182","author":"Rivers","year":"2018","journal-title":"Br J Haematol"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood.V90.8.2921","article-title":"High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt\u2019s lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry","volume":"90","author":"Ladenstein","year":"1997","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","article-title":"Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents","volume":"109","author":"Cairo","year":"2007","journal-title":"Blood"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/sj.bmt.1705948","article-title":"Stem cell transplantation for pediatric lymphoma: past, present and future","volume":"41","author":"Bradley","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"e27962","DOI":"10.1002\/pbc.27962","article-title":"Brentuximab vedotin as consolidation after hematopoietic cell transplant for relapsed Hodgkin lymphoma in pediatric patients","volume":"66","author":"Flerlage","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"ref481","first-page":"353","article-title":"Bone marrow transplantation in 46 pediatric patients with non-Hodgkin\u2019s lymphoma","volume":"15","author":"Bureo","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/MPH.0000000000001479","article-title":"What is the role of hematopoietic cell transplantation (HCT) for pediatric acute lymphoblastic leukemia (ALL) in the age of chimeric antigen receptor T-cell (CART) therapy?","volume":"41","author":"Taraseviciute","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1470-2045(19)30091-9","article-title":"Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study","volume":"20","author":"Tilly","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/8\/article-p1135.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/18\/8\/article-p1135.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T18:35:48Z","timestamp":1603478148000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/8\/article-p1135.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":104,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2020.7617","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}